Deep Brain Stimulation Devices Market to Remain Balanced During the Forecast Period 2026

Press Release

Deep brain stimulation (DBS) surgery is carried out as part of treatment of various neural debilitating conditions such as Parkinson’s disease, dementia, and Alzheimer’s disease. Patients fitted with a deep brain stimulation device can get long-term relief from debilitating symptoms of Parkinson’s disease. There is significant reduction in side-effects caused due to medications, though medications may be required in some patient post-surgery. The DBS device is mainly placed in one of the three FDA approved target sites in Parkinson’s disease. Most commonly preferred target sites are the Globus Pallidus Interna (GPi) and Subthalamic Nucleus (STN).

Get Sample Copy of Professional Insights: https://www.coherentmarketinsights.com/insight/request-sample/84

Market Dynamics

Aging increases the risk of Alzheimer’s disease, Parkinson’s disease and dementia. Thus, growing geriatric population is a major factor driving demand for deep brain stimulation devices. Though drug therapies are available for treating these diseases, surgical procedures are recommended in later stages of the condition. Furthermore, deep brain stimulation devices reduce the side effects and improves patient condition by reducing incidence of tremors. Patients are inclined towards adoption of minimally invasive procedures, as these require low healing time and leave behind minimal scars. Surgeons too prefer such procedures as it significantly reduces risk element from accidental damage to surrounding tissue. This is another factor fueling demand for deep brain stimulation devices globally. However, as these devices need to be implanted in the brain, it is extremely challenging and in turn reduces acceptance of DBS devices among patients.

Rising incidence rate of Parkinson’s disease is expected to fuel the deep brain stimulation devices market growth

According to the Parkinson’s disease Foundation, as of 2016, over 10 million people are suffering from Parkinson’s disease globally. The findings published by the organization showed that incidence rate of PD increases with age and only 4% of people were diagnosed with PD before the age of 50 years. According to the Parkinson’s disease Foundation, incidence rate of PD in the U.S is as high as 60,000 each year. According to Parkinson’s Australia Inc., around 11,544 new cases of PD were diagnosed in Australia in 2014 and as per the statistics released by Parkinson Canada, the number of people suffering from Parkinson’s disease in Canada is expected to increase to over 163,700 by 2031 (double than the prevalence in 2011). Therefore, increasing incidence of PD across the globe is projected to drive the deep brain stimulation devices market growth.

Development in technology to increase therapeutic outcome and enhance application of DBS in other disease treatment

According to a study published in the Neuron journal in December 2016, deep brain stimulation, targeting entorhinal cortex and hippocampus regions in the brain, demonstrated negative impact on improving memory. Researchers, however, are optimistic about obtaining successful results through further research in enhancing memory, especially in Alzheimer patients.

Activa PC+S system by Medtronic Inc., is a closed-loop DBS device being utilized for research purpose among few physicians in Europe. This system records the electrical activity in brain and develops an algorithm of the closed-loop system. The device is being tested in patients with advanced Parkinson’s disease. Once commercialized, the closed-loop DBS system would make treatment for Parkinson’s disease more effective and customized according to unique patient needs. This is expected to benefit patients significantly and thus augment the deep brain stimulation devices market development.

Increasing demand for minimally-invasive treatment options in emerging economies to create opportunities in the respective deep brain stimulation devices market

Parkinson’s and Alzheimer disease involves long-term administration of medications, making it unaffordable to major section of the population in emerging economies in Asia, Africa, and Latin America. Advent of minimally-invasive technology has led to increase in demand for such procedures and devices for treatment of chronic disease conditions such as diabetes, stroke, Parkinson’s disease, blood clot, and Alzheimer’s disease. Deep brain stimulation devices being an effective minimally-invasive therapy for Parkinson’s patients, is projected to gain significant growth traction in emerging economies such as India, China, Brazil, Israel, and North African countries. This in-turn is expected to fuel the deep brain stimulation devices market growth.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/84

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar